Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION JMA’s Nakagawa Questions Price Difference for LLPs and AGs, Negative about PhRMA Pitch for AWP Alternatives
June 9, 2017
-
BUSINESS FDA Accepts Sawai’s ANDA for Tecfidera Generic
June 8, 2017
-
BUSINESS Pfizer Boosting Global Oncology Footprint with Diverse Portfolio: SVP
June 7, 2017
-
BUSINESS Discontinuation of Development Continues for Novel Diabetes Drugs, Including Daiichi Sankyo’s GPR119 Agonist
June 6, 2017
-
BUSINESS AbbVie to Seek Indication Expansions for Humira, Competing with Biosimilars on the Strength of Original Product’s Reliability
June 5, 2017
-
REGULATORY Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
June 5, 2017
-
REGULATORY 4 Eligibility Criteria Presented for Conditional Early Approval System
June 2, 2017
-
REGULATORY Honebuto Policy to Incorporate Timeline for Drug Pricing Overhaul
June 2, 2017
-
REGULATORY Payer Reps Push Earlier Application of “Z2” Price Cut for LLPs with Low Gx Rates: Chuikyo
June 1, 2017
-
BUSINESS FY2016 Earnings Roundup - 3: Price Battle Batters Generic Makers, 3 Majors’ Profit Rate in Single-Digits
May 31, 2017
-
BUSINESS FY2016 Earnings Roundup - 2: Entyvio Robust, Xtandi Treads Water as Global Brands Underpin Revenue
May 30, 2017
-
BUSINESS FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
May 29, 2017
-
REGULATORY MOF Panel Calls for Abolishing Price Maintenance Premium, Further Belt-Tightening
May 26, 2017
-
BUSINESS Ninlaro Makes Japan Debut, Mundesine Now Also Available
May 25, 2017
-
REGULATORY Health Minister Pitches Revision to Corporate Eligibility Criteria for Price Maintenance Premium: CEFP
May 24, 2017
-
REGULATORY MHLW to Set Deadline to Achieve 80% Generic Goal for “September 2020”
May 23, 2017
-
TRENDS Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
-
REGULATORY Global Headquarters Watching Japan, Keep Drug Prices for Patented Period: PhRMA, EFPIA
May 19, 2017
-
REGULATORY Social Security Council Subcommittee Negative about Reference Pricing System
May 18, 2017
-
REGULATORY (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…